Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Americas Silver Corporation Provides First Quarter Production and Cost Update

Published

on

Reading Time: 9 minutes

TORONTO–(BUSINESS WIRE)–Americas Silver Corporation (TSX: USA) (NYSE American: USAS) (“Americas
Silver” or the “Company”) today announced production and operating cost
results for the first quarter of 2019 on a consolidated basis and
individually for its Cosalá Operations and Galena Complex. All figures
are in U.S. dollars unless otherwise indicated.

First Quarter Highlights

  • Consolidated silver production of approximately 1.8 million silver
    equivalent1 ounces, an increase of 9% year-over-year, and
    395,000 silver ounces consistent with prior year.
  • Consolidated cash costs2 were approximately negative
    ($0.50) per silver ounce, a decrease of 144%, when compared to prior
    quarter. Consolidated all-in sustaining costs2 (“AISC”)
    were approximately $5.54 per silver ounce, a decrease of 53%, when
    compared to Q4 2018.
  • Milled tonnage at the Cosalá Operations increased by 24%
    year-over-year, with the San Rafael mine sustaining an average milling
    rate of approximately 1,750 tonnes per operating day. Production of
    approximately 1.3 million silver equivalent ounces including
    approximately 170,000 silver ounces, representing increases of 39% and
    118%, respectively, year-over-year. Cash costs were approximately
    negative ($30.48) per silver ounce and AISC were approximately
    negative ($25.85) per silver ounce representing decreases of 21% and
    130%, respectively, when compared to prior quarter.
  • Continuing operational challenges limited production at the Galena
    Complex to approximately 430,000 silver equivalent ounces including
    approximately 220,000 silver ounces, representing decreases of 15% and
    1%, respectively, when compared to prior quarter. Cash costs were
    approximately $23.03 per silver ounce and AISC were approximately
    $30.17 per silver ounce representing increases of 8% and 2%,
    respectively, when compared to prior quarter.
  • Subsequent to quarter end, the acquisition of Pershing Gold
    Corporation (“Pershing”) closed on April 3, 2019 after the Committee
    on Foreign Investment in the United States (“CFIUS”) completed its
    review. The Company announced concurrent financing signed with
    Sandstorm Gold Ltd. for gross proceeds of approximately US$42.5
    million to completely fund production at the Relief Canyon Project.
  • Guidance for 2019 remains unchanged at 1.6 – 2.0 million silver ounces
    and 6.6 – 7.0 million silver equivalent ounces at cash costs of $4.00
    to $6.00 per silver ounce and AISC of $10.00 to $12.00 per silver
    ounce. The Company expects to release its first quarter financial
    results on or before May 14, 2019.

“The Cosalá Operations had an excellent quarter mining and processing an
average of approximately 1,750 tonnes per operating day, resulting in
greater silver and by-product metal production, with lower cash costs
and AISC,” said Americas Silver President and CEO Darren Blasutti.
“Construction activity at Relief Canyon is ramping up and orders for
long-lead items have been placed as the Company advances this project
towards pouring gold before the end of the year. With the addition of
this new mine, the Company expects to increase precious metal production
by over 500% by 2021.”

Consolidated First Quarter Production Details

Consolidated silver production for the first quarter of 2019 was 393,824
ounces, which was largely consistent with both the prior quarter and
year-over-year. Silver equivalent production was approximately 1.8
million ounces, an increase of 9% year-over-year. Consolidated cash
costs decreased 144% to negative ($0.50) per silver ounce compared to
the prior quarter and increased 82% year-over-year, and AISC decreased
53% to $5.54 per silver ounce compared to the prior quarter and
decreased 10% year-over-year. Consolidated zinc production increased by
10% compared to the prior quarter and 54% year-over-year, while
consolidated lead production decreased by 10% compared to the prior
quarter and increased by 8% year-over-year.

 

 

Table 1
Consolidated Production Highlights

 

    Q1 2019   Q1 2018   Change   Q4 2018   Change
Processed Ore (tonnes milled)   182,029   163,875   11%   186,585   -2%
Silver Production (ounces)   393,824   397,035   -1%   395,294   -1%
Silver Equivalent Production (ounces)   1,754,839   1,613,711   9%   1,799,741   -2%
Silver Grade (grams per tonne)   87   95   -8%   87   0%
Cost of Sales ($ per equiv. ounce silver)   $7.11   $8.14   -13%   $7.87   -10%
Cash Costs ($ per ounce silver)   ($0.50)   ($2.73)   82%   $1.14   -144%
AISC ($ per ounce silver)   $5.54   $6.17   -10%   $11.78   -53%
Zinc Production (pounds)   11,263,623   7,332,978   54%   10,223,692   10%
Lead Production (pounds)   8,211,429   7,624,685   8%   9,088,862   -10%

Cosalá Operations Production Details

The Cosalá Operations produced 173,169 ounces of silver during the first
quarter of 2019 and 1,322,045 ounces of silver equivalent during the
same period at cash costs of negative ($30.48) per silver ounce and AISC
of negative ($25.85) per silver ounce. Silver production increased by
118% year-over-year and consistent with the fourth quarter 2018, while
silver equivalent production increased by 39% year-over-year and 3% over
the prior quarter. Cash costs and AISC improved by 21% and 130%,
respectively, compared to the Q4 2018.

 

Table 2
Cosalá Operations Highlights

 

    Q1 2019   Q1 2018   Change   Q4 2018   Change
Processed Ore (tonnes milled)   152,605   123,285   24%   149,577   2%
Silver Production (ounces)   173,169   79,382   118%   172,016   1%
Silver Equivalent Production (ounces)   1,322,045   948,081   39%   1,287,657   3%
Silver Grade (grams per tonne)   57   42   36%   59   -3%
Cost of Sales ($ per equiv. ounce silver)   $4.35   $5.92   -27%   $4.66   -7%
Cash Costs ($ per ounce silver)   ($30.48)   ($59.52)   -49%   ($25.12)   21%
AISC ($ per ounce silver)   ($25.85)   ($36.28)   -29%   ($11.26)   130%
Zinc Production (pounds)   11,263,623   7,332,978   54%   10,223,692   10%
Lead Production (pounds)   4,626,233   2,679,485   73%   4,388,146   5%

Strong results were driven by sustained improvements in grade, mill
throughput and metal recovery to concentrate. Site expenditures tracked
expectations. Development of the incline ramp toward San Rafael’s Upper
Zone has resumed and is advancing ahead of plan. Ore production from the
Main Zone benefited from the additional working headings providing
operational flexibility. Further, mined head grades exceeded budgeted
head grades during the quarter. Any potential reduction in head grades
over the remainder of the year are expected to be largely offset by
further gains in mill throughput and metal recovery as additional
flotation capacity is installed during the second quarter.

Galena Complex Production Details

Unplanned mill downtime due to problems with the mill pinion bearing at
the Galena mine in January set the year off on a challenging note
however the underlying issues were successfully resolved during the
quarter. Performance trended back up until two separate ground falls
delayed production from two high-tonnage stopes. The cumulative impact
was the loss of nearly one month’s production during the quarter.
Performance is slowly improving and should return to expected levels by
the end of Q2 2019. Management remains committed to returning the
operation to an acceptable level of performance.

As a result of these unexpected incidents, the Galena Complex produced
220,655 ounces of silver during Q1 2019 and 432,794 ounces of silver
equivalent at cash costs of $23.03 per silver ounce and AISC of $30.17
per silver ounce. Silver and silver equivalent production decreased by
1% and 15%, respectively, compared to the prior quarter, and 31% and
35%, respectively, year-over-year. Cash costs and AISC increased by 8%
and 2%, respectively, due to the noted operational challenges.

 

Table 3
Galena Complex Highlights

 

    Q1 2019   Q1 2018   Change   Q4 2018   Change
Processed Ore (tonnes milled)   29,424   40,590   -28%   37,008   -20%
Silver Production (ounces)   220,655   317,653   -31%   223,278   -1%
Silver Equivalent Production (ounces)   432,794   665,630   -35%   512,084   -15%
Silver Grade (grams per tonne)   242   256   -5%   199   22%
Cost of Sales ($ per equiv. ounce silver)   $15.55   $11.31   38%   $15.95   -2%
Cash Costs ($ per ounce silver)   $23.03   $11.46   101%   $21.36   8%
AISC ($ per ounce silver)   $30.17   $16.78   80%   $29.52   2%
Lead Production (pounds)   3,585,196   4,945,200   -28%   4,700,716   -24%

Relief Canyon Update

On April 3, 2019, the Company announced the closing of the Pershing
acquisition after receiving notification that CFIUS completed its
review. The Company also announced a financing package of $42.5 million
secured from Sandstorm Gold Ltd. to fully fund the development of Relief
Canyon and Board approval for construction commencement at the Project
with the intention of pouring gold before year end. Since that time,
orders have been placed for long-lead items such as the mill liners,
crusher and conveyor system and negotiations have commenced on the leach
pad construction and mining contracts. Expected start dates are mid-May
and mid-June respectively. Further information on the Relief Canyon
development will be made available periodically on the Company’s website
as construction progresses at www.americassilvercorp.com.

Americas Silver Annual and Special Meeting

The annual and special meeting of Americas Silver is scheduled for 3pm
(EDT) on Wednesday May 15, 2019 at Vantage Venues, 150 King St. West,
Toronto, Ontario.

Your vote is important. Please vote before the proxy vote deadline on
May 13, 2019 at 3pm (EDT).

Additional information concerning the annual and special meeting can be
found in the Management Information Circular dated April 18, 2019. An
electronic copy of the Circular is available online under the Company’s
profile at www.sedar.com
or at www.americassilvercorp.com.

About Americas Silver Corporation

Americas Silver is a precious metal mining company focused on growth
from its existing asset base and execution of targeted accretive
acquisitions. It owns and operates the Cosalá Operations in Sinaloa,
Mexico and the Galena Complex in Idaho, USA. The Company expects to
begin producing gold in the fourth quarter of 2019 at its fully-funded
Relief Canyon Project, in Nevada, USA which is currently in
construction. For further information, please see SEDAR or
americassilvercorp.com.

Cautionary Statement on Forward-Looking Information:

This news release contains “forward-looking information” within the
meaning of applicable securities laws. Forward-looking information
includes, but is not limited to, Americas Silver’s expectations,
intentions, plans, assumptions and beliefs with respect to, among other
things, Americas Silver’s financing efforts; construction, production,
and development plans at the Relief Canyon Project and performance
expectations for the Relief Canyon Project and impact on Americas
Silver’s financial performance; and the estimated construction timeline
and costs for the Relief Canyon Project; the estimated timeline for
environmental approvals for the second phase of the Relief Canyon
Project; and the impact of the Transaction on the liquidity of the
Company’s shares. Often, but not always, forward-looking information can
be identified by forward-looking words such as “anticipate”, “believe”,
“expect”, “goal”, “plan”, “intend”, “potential’, “estimate”, “may”,
“assume” and “will” or similar words suggesting future outcomes, or
other expectations, beliefs, plans, objectives, assumptions, intentions,
or statements about future events or performance. Forward-looking
information is based on the opinions and estimates of Americas Silver as
of the date such information is provided and is subject to known and
unknown risks, uncertainties, and other factors that may cause the
actual results, level of activity, performance, or achievements of
Americas Silver to be materially different from those expressed or
implied by such forward-looking information. With respect to the
Sandstorm financing, risks and uncertainties include the ability of the
Company and its subsidiaries to fulfill the conditions to drawing all
the available funds under the purchase agreement and convertible
debenture and the potential for, and consequences of, default
thereunder. With respect to the business of Americas Silver, these risks
and uncertainties include interpretations or reinterpretations of
geologic information; unfavorable exploration results; inability to
obtain permits required for future exploration, development or
production; general economic conditions and conditions affecting the
industries in which the Company operates; the uncertainty of regulatory
requirements and approvals; fluctuating mineral and commodity prices;
the ability to obtain necessary future financing on acceptable terms or
at all; the ability to develop, complete construction and operate the
Relief Canyon Project; and risks associated with the mining industry
such as economic factors (including future commodity prices, currency
fluctuations and energy prices), ground conditions and other factors
limiting mine access, failure of plant, equipment, processes and
transportation services to operate as anticipated, environmental risks,
government regulation, actual results of current exploration and
production activities, possible variations in ore grade or recovery
rates, permitting timelines, capital and construction expenditures,
reclamation activities, labor relations, social and political
developments and other risks of the mining industry. Although the
Company has attempted to identify important factors that could cause
actual results to differ materially from those contained in
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated, or intended. Readers are
cautioned not to place undue reliance on such information. Additional
information regarding the factors that may cause actual results to
differ materially from this forward‐looking information is available in
Pershing Gold’s filings with the SEC, including the Annual Report on
Form 10‐K for the year ended December 31, 2017 and the Proxy Statement
of Pershing Gold dated November 29, 2018, and in Americas Silver’s
filings with the Canadian Securities Administrators on SEDAR and with
the SEC, including the management information circular of Americas
Silver dated December 4, 2018. Americas Silver does not undertake any
obligation to update publicly or otherwise revise any forward-looking
information whether as a result of new information, future events or
other such factors which affect this information, except as required by
law. Americas Silver does not give any assurance (1) that Americas
Silver will achieve its expectations, or (2) concerning the result or
timing thereof. All subsequent written and oral forward‐looking
information concerning Americas Silver, the Transaction, the Sandstorm
financing package, the combined Company or other matters attributable to
Americas Silver or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements above.

1 Silver equivalent production throughout this press release
was calculated based on silver, zinc, and lead realized prices during
each respective period.

2 Cash cost per ounce and all-in sustaining cost per ounce
are non-IFRS performance measures with no standardized definition. For
further information and detailed reconciliations, please refer to the
Company’s 2018 year-end and quarterly MD&A. The performance measures for
the quarter ended March 31, 2019 are preliminary throughout this press
release subject to refinement from the Company’s first quarter financial
results to be released on or before May 14, 2019.

Contacts

Darren Blasutti
President and CEO
Americas Silver Corporation
416‐848‐9503


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania